AstraZeneca: no time for time-wasting

Scott Alban, who is charged with protecting the innovation arising from AstraZeneca and its global biologics research and development (R&D) arm, MedImmune, spoke to LSIPR about protecting innovation, obtaining adequate protection and licensing at AstraZeneca, which invests approximately 25% of its revenue back into R&D annually.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BioNTech fires shots at Moderna's next-generation vaccine

20 February 2026 The German biotech claims the newly approved vaccine infringes its mRNA patent, deepening an already complex feud with billions of dollars at stake.

Americas

Abbott unit defends European protection for heart valve ‘cuff’ design

19 February 2026 An EPO appeals board has denied Boston Scientific’s bid to revoke St Jude Medical’s transcatheter aortic valve replacement (TAVR) patent, but declined to hand a complete victory to the patent owner.

Americas

Natera targets ex-employee over mass file download before rival move

19 February 2026 The genetic testing firm claims that a former oncology specialist stole hundreds of confidential files in the dead of night, days before moving to a competitor.

More features

Wiggin’s new litigation partner deepens ‘technically complex’ offer

Could everyday hospital equipment be the next defence against counterfeit medicines?

BioNTech fires shots at Moderna's next-generation vaccine

Mintz gains ex-Winston & Strawn partner and ITC expert

Abbott unit defends European protection for heart valve ‘cuff’ design

Natera targets ex-employee over mass file download before rival move

Danaher moves to acquire Masimo in $9.9bn deal

Emotional Perception exclusive: ‘We are now very much open for business’

AstraZeneca: no time for time-wasting

More on this story

Editor's picks

Editor's picks

More features